College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, People's Republic of China.
Int J Nanomedicine. 2020 Jun 9;15:4049-4062. doi: 10.2147/IJN.S237156. eCollection 2020.
Calcium carbonate (CC) nanoparticles have broad biomedical utilizations, owing to their multiple intrinsic merits. However, bare CC nanoparticles do not allow for the development of multifunctional devices suitable for advanced drug delivery in cancer therapy.
Phospholipid-modified phospholipid-CC hybrid nanoparticles were prepared in our study using a combination of vapor-diffusion and solvent-diffusion methods to offer optimized pharmaceutical capabilities.
Considering that particle size is a critical parameter that plays an important role in both in vitro and in vivo behaviors of nanoparticles, we here for the first time a present detailed protocol for the size-controlled preparation of hybrid nanoparticles, as well as analysis of the in vitro/in vivo behaviors of differently sized hybrid nanoparticles.
Our results might significantly advance the application of this promising material in more varied fields.
碳酸钙(CC)纳米粒子由于其多种内在优点,具有广泛的生物医学应用。然而,裸 CC 纳米粒子不允许开发多功能设备,这些设备适用于癌症治疗中的先进药物输送。
本研究采用气相扩散和溶剂扩散相结合的方法制备了磷脂修饰的磷脂-CC 杂化纳米粒子,以提供优化的药物性能。
考虑到粒径是纳米粒子在体外和体内行为中起重要作用的关键参数,我们首次提出了一种详细的方案,用于控制杂化纳米粒子的粒径,并分析不同粒径的杂化纳米粒子的体外/体内行为。
我们的结果可能会显著推动这种有前途的材料在更多领域的应用。